Related Experiment Videos
Adoptive cellular immunotherapy with CD19-specific T cells.
C Rössig1, S Pscherer, S Landmeier
1University Children's Hospital Münster, Department of Pediatric Hematology and Oncology, Münster. rossig@uni-muenster.de
Klinische Padiatrie
|November 25, 2005
Summary
Gene-modified T cells targeting CD19 show promise for treating relapsed acute lymphoblastic leukemia (ALL). Enhancing these cells with CD28 improves their proliferation, offering a potential new therapy for ALL relapse.
Area of Science:
- Immunology
- Oncology
- Gene Therapy
Background:
- Relapsed high-risk acute lymphoblastic leukemia (ALL) lacks effective treatments.
- Current adoptive cellular immunotherapy is limited by graft-versus-host disease (GVHD).
Purpose of the Study:
- To develop an immunotherapeutic strategy for targeted elimination of residual leukemic blasts in ALL.
- To engineer T cells for enhanced anti-leukemia activity.
Main Methods:
- Human T cells were genetically modified to express CD19-specific chimeric receptors.
- The CD28 costimulatory molecule's signaling domain was integrated to enhance T cell proliferation.
Main Results:
- Gene-modified T cells effectively lysed CD19-expressing ALL cells.
- T cell proliferation was limited upon CD19 stimulation alone.
- Integration of CD28 enhanced the proliferative response of gene-modified T cells.
Conclusions:
- Adoptive transfer of gene-modified T cells offers a potential strategy for preventing and treating ALL relapses.
- This approach may be particularly useful following allogeneic stem cell transplantation.